Pyridopyrimidine Derivatives as Selective PDE4 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for treating inflammatory and immune disorders, such as asthma and psoriasis, are limited by significant side effects like nausea and gastric acid secretion, necessitating the development of more effective and safer therapeutic agents.
Innovation Solution
Development of novel pyridopyrimidine derivatives that act as selective inhibitors of human PDE4, potentially offering improved therapeutic ratios with reduced side effects by modulating cAMP levels and downstream signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE4 inhibitors are used to treat inflammatory and immune disorders, then therapeutic efficacy is improved, but side effects such as nausea and gastric acid secretion increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PDE4 inhibitors through various substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20) on the pyridopyrimidine core structure. These structural parameter changes aim to optimize the balance between therapeutic efficacy and reduction of emetic side effects, as evidenced by the extensive structural variations presented in the patent that seek to improve the therapeutic ratio.
2Productivity
If first generation PDE4 inhibitors are used, then significant anti-inflammatory effects are achieved, but emetic side effects are prominent
Solution Approach 1:
The patent applies local quality by introducing specific substituents at different positions (R1 through R20) on the pyridopyrimidine core structure. Each position can be independently modified with different chemical groups to locally alter the molecule's properties, thereby optimizing the balance between anti-inflammatory efficacy and reduction of emetic side effects. This localized modification approach allows for fine-tuning of the drug's therapeutic profile.
Solution Approach 2:
The patent employs composite material principles by combining the pyridopyrimidine core structure with various heteroaryl, aryl, and heterocyclic substituents to create composite molecular structures. These composite structures integrate multiple functional groups that work synergistically to enhance anti-inflammatory effects while reducing emetic side effects, as demonstrated by the complex multi-substituted compounds described in the patent.
3Reliability
If PDE4 inhibition is increased to enhance therapeutic effect, then cAMP accumulation is improved, but gastric acid secretion and nausea increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the chemical parameters of PDE4 inhibitors through different substituents at multiple positions on the pyridopyrimidine core. These parameter changes are designed to modulate the degree of PDE4 inhibition and cAMP accumulation to achieve optimal therapeutic effects while minimizing gastric acid secretion and nausea. The extensive structural variations presented demonstrate this parameter optimization approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pyridopyrimidine derivatives effectively inhibit PDE4, providing a promising approach to treat inflammatory and immune disorders with reduced side effects, enhancing the therapeutic ratio and modulating cAMP homeostasis.
Implementation Method 1
Phosphodiesterases (PDEs) work by converting cAMP or cGMP to AMP and GMP... The inhibition of PDEs leads to the accumulation of cAMP or cGMP... PDE4 has been found to be the predominant cAMP metabolising isozyme family... The present invention discloses novel pyridopyrimidine derivatives that are inhibitors of human PDE4
Data Source
AI summary
The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.